Number of patients with response/total number of patients, n/N (%)
Visit Week IR-XR post48a IR-IR post48b XR-XR post48c Total
Week 48 125/130 (96.2) 11/12 (91.7) 268/276 (97.1) 404/418 (96.7)
Week 60 122/130 (93.8) 9/12 (75.0) 253/274 (92.3) 384/416 (92.3)
Week 72 124/130 (95.4) 9/9 (100) 265/271 (97.8) 398/410 (97.1)
Week 84 118/125(94.4) 7/8 (87.5) 244/268 (91.0) 369/401 (92.0)
Week 96 117/124 (94.4) 9/9 (100) 242/263 (92.0) 368/396 (92.9)
Week 108 119/125 (95.2) 8/9 (88.9) 247/260 (95.0) 374/394 (94.9)
Week 120 112/121 (92.6) 7/8 (87.5) 235/258 (91.1) 354/387 (91.5)
Week 132 115/121 (95.0) 6/7 (85.7) 238/252 (94.4) 359/380 (94.5)
Week 144 115/121 (95.0) 7/7 (100) 238/250 (95.2) 360/378 (95.2)
Last available visit 121/130 (93.1) 11/13 (84.6) 261/276 (94.6) 393/419 (93.8)
Notes: FAS=full analysis set; IR=immediate release; LLOQ=lower level of quantification; NVP=nevirapine; XR=extended release.
aPatients who received NVP IR during the first 48 weeks, and then switched to NVP XR.
bPatients who remained on NVP IR after week 48.
cPatients who remained on NVP XR after week 48.
Table 2: Proportion of virologic response using LLOQ=50 copies/mL after week 48 by visit (FAS).
Goto home»